ReviewJournal of atherosclerosis and thrombosis2019
Assessment of HDL Cholesterol Removal Capacity: Toward Clinical Application.
Review in Journal of atherosclerosis and thrombosis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Cholesterol Uptake Capacity as a Prognostic Marker of Cardiovascular Events for Patients with Coronary Artery Disease.Journal of atherosclerosis and thrombosis · 2025Observational
- The Connection Between Lipid Metabolism in the Heart and Liver of Wuzhishan Pigs.Biomolecules · 2025Article
- Assessing stroke recurrence in sICAS: a study on mCSVD score and culprit plaque magnetic resonance characteristics.Frontiers in neurology · 2024Article
- Cholesterol Absorption and Synthesis Markers: Risk for Cardiovascular Diseases?Journal of atherosclerosis and thrombosis · 2023Article
- Fish-Derived Omega-3 Fatty Acids: Guardians of High-Density Lipoprotein?Journal of atherosclerosis and thrombosis · 2023Article
- Small High-Density Lipoprotein and Omega-3 Fatty Acid Intake Differentiates Japanese and Japanese-Americans: The INTERLIPID Study.Journal of atherosclerosis and thrombosis · 2023Article
- Association of ANGPTL3 polymorphisms with high-density lipoprotein cholesterol uptake capacity in patients with cardiovascular disease.Journal of clinical laboratory analysis · 2021Article
- Effects of Elaidic Acid on HDL Cholesterol Uptake Capacity.Nutrients · 2021Article
- Current Status of Familial LCAT Deficiency in Japan.Journal of atherosclerosis and thrombosis · 2021Review
- Serum HDL cholesterol uptake capacity in subjects from the MASHAD cohort study: Its value in determining the risk of cardiovascular endpoints.Journal of clinical laboratory analysis · 2021Article
- Review
- Changing Perspectives on HDL: From Simple Quantity Measurements to Functional Quality Assessment.Journal of lipids · 2021Review
- Effects of particulate matter on atherosclerosis: a link via high-density lipoprotein (HDL) functionality?Particle and fibre toxicology · 2020Review
- A Novel Indicator for HDL Functionality.Journal of atherosclerosis and thrombosis · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While there is a controversy regarding the causal relationship between high-density lipoprotein cholesterol (HDL-C) and cardiovascular disease (CVD), recent studies have demonstrated that the cholesterol efflux capacity (CEC) of HDL is associated with the incidence of CVD. However, there are several limitations to current assays of CEC. First, CEC measurements are not instantly applicable in clinical settings, because CEC assay methods require radiolabeled cholesterol and cultured cells, and these procedures are time consuming. Second, techniques to measure CEC are not standardized. Third, the condition of endogenous cholesterol donors would not be accounted for in the CEC assays. Recently, we established a simple, high-throughput, cell-free assay system to evaluate the capacity of HDL to accept additional cholesterol, which is herein referred to as "cholesterol uptake capacity (CUC)". We demonstrated that CUC represents a residual cardiovascular risk in patients with optimal low-density lipoprotein cholesterol control independently of traditional risk factors, including HDL-C. Establishing reproducible approaches for the cholesterol removal capacity of HDL is required to validate the impact of dysfunctional HDL on cardiovascular risk stratification in the "real world".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.